Table 4 Grade 3/4 adverse events per patient treated at the MTD (all cycles)

From: Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer

 

NCI-CTC grade, n (%) (N =29)

Event

3

4

Haematological

 Anaemia

0

0

 Leucopaenia

1 (3)

0

 Neutropaenia

1 (3)

0

 Thrombocytopaenia

0

0

Non-haematological

 Alopecia

NA

NA

 Anorexia

0

0

 Lethargy

1 (3)

0

 Nausea

0

0

 Vomiting

0

0

 Diarrhoea

3 (10)

0

 Constipation

0

0

 AST elevation

1 (3)

0

 Neuropathy

1 (3)

0

 Hand–foot syndrome

0

0

 Infection

0

0

 Abdominal pain

2 (7)

0

 Cardiac

0

1 (3)

  1. AST=aspartate aminotransferase; MTD=maximum tolerated dose; NA=not applicable; NCI-CTC=National Cancer Institute Common Toxicity Criteria.
Back to article page